Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.36 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.36 |
| ▸ | ATM | Q13315 | 1/20 | 0.36 |
| ▸ | CA12 | O43570 | 1/20 | 0.31 |
| ▸ | CA1 | P00915 | 1/20 | 0.31 |
| ▸ | CA2 | P00918 | 1/20 | 0.31 |
| ▸ | CA9 | Q16790 | 1/20 | 0.31 |
| ▸ | MEN1 | O00255 | 1/20 | 0.30 |
| ▸ | POLB | P06746 | 1/20 | 0.30 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.30 |
| ▸ | ABL1 | P00519 | 1/20 | 0.30 |
| ▸ | TYMS | P04818 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16282125 | 0.96 | KDM4E (0.36) | KDM4EMAPK1ATMMEN1POLB | |
| SCHEMBL25915595 | 0.94 | KDM4E (0.36) | KDM4EMAPK1ATMMEN1POLB | |
| SCHEMBL25915784 | 0.92 | ATM (0.36) | KDM4EMAPK1ATMCA12CA1 | |
| SCHEMBL18021825 | 0.91 | KDM4E (0.43) | KDM4EMAPK1ATMMEN1POLB | |
| SCHEMBL25915594 | 0.90 | KDM4E (0.34) | KDM4EMAPK1ATM | |
| SCHEMBL18021824 | 0.90 | KDM4E (0.44) | KDM4EMAPK1ATMMEN1POLB | |
| SCHEMBL18021767 | 0.90 | KDM4E (0.44) | KDM4EMAPK1ATMMEN1POLB | |
| SCHEMBL25915599 | 0.89 | ATM (0.33) | KDM4EMAPK1ATMMEN1KMT2A | |
| SCHEMBL16282146 | 0.88 | KDM4E (0.37) | KDM4EMAPK1ATMCA12CA1 | |
| SCHEMBL16282193 | 0.88 | MEN1 (0.32) | KDM4EMAPK1ATMMEN1POLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230240134-A1 | HETEROCYCLIC COMPOUND AND ORGANIC LIGHT-EMITTING DEVICE COMPRISING SAME | LT MATERIALS CO., LTD. (KR) | 2023-07-27 | — | — | US | disclosed |
| US-20230240134-A1 | HETEROCYCLIC COMPOUND AND ORGANIC LIGHT-EMITTING DEVICE COMPRISING SAME | LT MATERIALS CO., LTD. (KR) | 2023-07-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230240134-A1 | HETEROCYCLIC COMPOUND AND ORGANIC LIGHT-EMITTING DEVICE COMPRISING SAME | CRY1, CYP1A1, CYP1B1 | KDM4E 2673/4885MAPK1 681/4885ATM 3135/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.